Biotechnology - Licensing, Ophthalmics

Filter

Current filters:

LicensingOphthalmics

Popular Filters

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

Novartis in up to $1 billion deal to acquire ex-US rights to Fovista

20-05-2014

Swiss pharma major Novartis has signed a licensing and commercialization agreement with US biotech firm…

BiotechnologyFovistaLicensingNovartisOphthalmicsOphthotech

ThromboGenics explores “strategic options” for the company

ThromboGenics explores “strategic options” for the company

24-02-2014

Belgian biotech firm ThromboGenics revealed this morning that it has retained financial advisor Morgan…

AlconBiotechnologyLicensingMergers & AcquisitionsNovartisOphthalmicsThromboGenics

Oxford BioMedica concludes novel ocular license deal with Sanofi

Oxford BioMedica concludes novel ocular license deal with Sanofi

17-02-2014

UK-based Oxford BioMedica has concluded the terms of the development and commercialization license agreement…

BiotechnologyLicensingOphthalmicsOxford BioMedicaUK

Nicox granted exclusive promotion and marketing rights for AMD test in North America

17-01-2014

French biotech firm NicOx SA (NYSE Euronext Paris: COX) and USA-based Sequenom (Nasdaq: SQNM) have entered…

BiotechnologyFranceLicensingNicOxOphthalmicsSequenomUSA

Regeneron and Bayer expand deal to develop new option for wet-AMD

Regeneron and Bayer expand deal to develop new option for wet-AMD

14-01-2014

US biotech firm Regeneron Pharmaceuticals said yesterday that it has expanded its accord with German…

BayerBiotechnologyEyleaLicensingOphthalmicsRegeneronResearch

Biocon and Quark Pharma collaborate on novel siRNA based therapeutics

18-12-2013

India-based biotech firm Biocon and the USA’s Quark Pharmaceuticals have entered into a licensing and…

BioconBiotechnologyLicensingOphthalmicsQuark PharmaceuticalsResearch

Back to top